Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.
TLDR
In this article, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET), and the equivalent emergence of primary myelofibrosis (PMF).Abstract:
Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms (MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling of the bone marrow niche in a manner that promotes malignant over non-malignant hematopoiesis. This take-over of hematopoiesis by the malignant clone is hypothesized to include hyperactivation of inflammatory signaling and overproduction of inflammatory cytokines. In the Ph-negative MPNs, inflammatory cytokines are considered to be responsible for a highly deleterious pathophysiologic process: the phenotypic transformation of polycythemia vera (PV) or essential thrombocythemia (ET) to secondary myelofibrosis (MF), and the equivalent emergence of primary myelofibrosis (PMF). Bone marrow fibrosis itself is thought to be mediated heavily by the cytokine TGF-β, and possibly other cytokines produced as a result of hyperactivated JAK2 kinase in the malignant clone. MF also features extramedullary hematopoiesis and progression to bone marrow failure, both of which may be mediated in part by responses to cytokines. In MF, elevated levels of individual cytokines in plasma are adverse prognostic indicators: elevated IL-8/CXCL8, in particular, predicts risk of transformation of MF to secondary AML (sAML). Tumor necrosis factor (TNF, also known as TNFα), may underlie malignant clonal dominance, based on results from mouse models. Human PV and ET, as well as MF, harbor overproduction of multiple cytokines, above what is observed in normal aging, which can lead to cellular signaling abnormalities separate from those directly mediated by hyperactivated JAK2 or MPL kinases. Evidence that NFκB pathway signaling is frequently hyperactivated in a pan-hematopoietic pattern in MPNs, including in cells outside the malignant clone, emphasizes that MPNs are pan-hematopoietic diseases, which remodel the bone marrow milieu to favor persistence of the malignancy. Clinical evidence that JAK2 inhibition by ruxolitinib in MF neither reliably reduces malignant clonal burden nor eliminates cytokine elevations, suggests targeting cytokine mediated signaling as a therapeutic strategy, which is being pursued in new clinical trials. Greater knowledge of inflammatory pathophysiology in MPNs can therefore contribute to the development of more effective therapy.read more
Citations
More filters
Journal ArticleDOI
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML
Lionel Ades,Larisa Girshova,Vadim A Doronin,María Díez-Campelo,David Valcárcel,Suman Kambhampati,Nora Viniou,Dariusz Woszczyk,R. de Paz Arias,Argiris Symeonidis,Achilles Anagnostopoulos,Eduardo Munhoz,Uwe Platzbecker,Valeria Santini,Robert Fram,Ying Yuan,Sharon Friedlander,Douglas V. Faller,Mikkael A. Sekeres +18 more
TL;DR: The results underscore the importance of large, randomized controlled trials in these heterogeneous myeloid diseases and the value of remaining on therapy >3 cycles.
Journal ArticleDOI
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
TL;DR: In this paper , the PD-1/PD-L1 pathway activated in immune microenvironment, the milieu of BM shift to immunosuppressive, contributing to a clonal evolution of blasts.
Journal ArticleDOI
Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
Naveen Pemmaraju,Jacqueline S. Garcia,Jalaja Potluri,Jason G. Harb,Yan Sun,P. Soo Jung,Q. Qin,Srinivas K. Tantravahi,Srdan Verstovsek,Claire N. Harrison +9 more
TL;DR: This article showed that the addition of navitoclax to ruxolitinib induced a 35% or greater reduction in spleen volume (SVR35) and reduced symptoms in patients with myelofibrosis no longer benefiting from ruxolaxinib.
Journal ArticleDOI
Defining disease modification in myelofibrosis in the era of targeted therapy
TL;DR: In this article , the authors discuss recent clinical trial data of agents in development and dissect the potential for novel end points to act as disease modifying parameters, using the rationale garnered from latest clinical and scientific evidence, the authors propose a definition of disease modification in myelofibrosis.
Journal ArticleDOI
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Srdan Verstovsek,Haifa Kathrin Al-Ali,John Mascarenhas,Andrew C. Perkins,Alessandro M. Vannucchi,Sanjay R. Mohan,Bart L. Scott,Dariusz Woszczyk,Steffen Koschmieder,Regina Garcia-Delgado,Rejtő László,Jesse McGreivy,Wayne Rothbaum,Jean-Jacques Kiladjian +13 more
TL;DR: Navtemadlin (KRT-232) as mentioned in this paper restores p53 activity to drive apoptosis of wild-type TP53 tumor cells by inducing expression of pro-apoptotic Bcl-2 family proteins.
References
More filters
Journal ArticleDOI
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
Hans Michael Kvasnicka,Jürgen Thiele,Carlos E. Bueso-Ramos,William Sun,Jorge E. Cortes,Hagop M. Kantarjian,Srdan Verstovsek +6 more
TL;DR: The finding that long-term ruxolitinib therapy may reverse or markedly delay BM fibrosis progression in advanced MF suggests that sustained JAK inhibition may be disease-modifying.
Journal ArticleDOI
Constitutive NF-κB activation in AML: Causes and treatment strategies
TL;DR: The underlying molecular mechanisms leading to constitutive NF-κB activity are described and the novel treatment strategies based on the inhibition of NF-σκB activation are discussed.
Journal ArticleDOI
Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation
Sebastien Jacquelin,Jasmin Straube,Leanne Cooper,Therese Vu,Axia Song,Megan Bywater,Eva Baxter,Matthew Heidecker,Brad Wackrow,Amy H. Porter,Victoria Ling,Joanne Green,Rebecca Austin,Stephen H. Kazakoff,Nicola Waddell,Luke B. Hesson,Luke B. Hesson,John E. Pimanda,Frank Stegelmann,Lars Bullinger,Konstanze Döhner,Raajit K. Rampal,Dirk Heckl,Geoffrey R. Hill,Geoffrey R. Hill,Geoffrey R. Hill,Steven W. Lane,Steven W. Lane,Steven W. Lane +28 more
TL;DR: This work identifies mutational cooperation between Jak2V617F expression and Dnmt3a loss that drives progression from early-stage polycythemia vera to advanced myelofibrosis and activation of HSPC enhancer-driven inflammatory signaling.
Journal ArticleDOI
Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments.
Kenneth D. Gibbs,Penney M. Gilbert,Karen Sachs,Feifei Zhao,Helen M. Blau,Irving L. Weissman,Garry P. Nolan,Ravindra Majeti +7 more
TL;DR: Single-cell phospho-specific flow cytometry was used to define the signaling networks active in 5 previously defined human HSPC subsets and revealed that the currently defined HSC compartment is composed of biochemically distinct subsets with the ability to respond rapidly and directly in vitro to a broader array of cytokines than previously appreciated.
Journal ArticleDOI
Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F
Marjorie Boissinot,Marjorie Boissinot,Cédric Cleyrat,Mathias Vilaine,Yannick Jacques,Isabelle Corre,Sylvie Hermouet +6 more
TL;DR: There is evidence that inflammation-linked cytokines are required for the growth of JAK2V617F-mutated erythroid progenitors in Polycythemia vera, and blocking the c-MET/HGF/IL-11 pathways could be of interest as an additional therapeutic option in PV.